9/29
Inconc.
Late treatment study
et al., Research Square, doi:10.21203/rs.3.rs-83677/v1 (Preprint)
A Randomized Controlled Study Of Favipiravir Vs Hydroxych loroquine In COVID-19 Management: What Have We Learned So Far?
Small RCT comparing HC Q and favipiravir, with 50 patients in each arm, finding that 55.1% of HC Q patients were PCR negative on day 7 compared to 48% for favipiravir, p = 0.7. There was no comparison with a control group.